Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Current Assets (2016 - 2025)

iBio (IBIO) has disclosed Current Assets for 15 consecutive years, with $53.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 544.54% to $53.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $53.4 million, a 544.54% increase, with the full-year FY2025 number at $9.7 million, down 37.97% from a year prior.
  • Current Assets was $53.4 million for Q4 2025 at iBio, up from $50.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $107.2 million in Q1 2021 to a low of $6.1 million in Q1 2025.
  • A 5-year average of $43.2 million and a median of $37.2 million in 2022 define the central range for Current Assets.
  • Biggest YoY gain for Current Assets was 544.54% in 2025; the steepest drop was 83.12% in 2025.
  • iBio's Current Assets stood at $67.5 million in 2021, then plummeted by 43.35% to $38.2 million in 2022, then tumbled by 48.48% to $19.7 million in 2023, then tumbled by 57.94% to $8.3 million in 2024, then skyrocketed by 544.54% to $53.4 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Current Assets are $53.4 million (Q4 2025), $50.8 million (Q3 2025), and $9.7 million (Q2 2025).